NORTH CHICAGO, Ill., Oct. 27, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.
"We delivered another quarter of outstanding results driven by accelerating performance across our non-Humira growth platform, which is demonstrating double-digit growth," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Based upon the strength and momentum of our business, we are once again raising our full-year 2023 guidance as well as our floor EPS outlook for next year. We are also increasing our quarterly dividend, underscoring our confidence in AbbVie's long-term outlook."
Third-Quarter Results
Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. |
Recent Events
Full-Year 2023 Outlook
AbbVie is raising its adjusted diluted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23, which includes an unfavorable impact of $0.27 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2023. The company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2023, as both cannot be reliably forecasted.
AbbVie Raises 2024 EPS Guidance Floor
AbbVie is raising its adjusted diluted EPS guidance floor for the full year 2024 from $10.70 to $11.00, which excludes any impact from acquired IPR&D and milestones, as both cannot be reliably forecasted. This is an update to guidance that was initially issued in February 2023 as part of AbbVie's fourth quarter 2022 earnings call. As a result of this update, AbbVie does not expect adjusted diluted EPS for full year 2024 to be below $11.00 per share. The company will issue its formal 2024 adjusted diluted EPS guidance range in conjunction with fourth quarter 2023 results.
Company Declares Dividend Increase of 4.7 Percent
AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.48 per share to $1.55 per share beginning with the dividend payable on February 15, 2024 to shareholders of record as of January 16, 2024. This reflects an increase of approximately 4.7 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by more than 285 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience and eye care - and products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X (formerly Twitter), Facebook, Instagram, YouTube or LinkedIn.
Conference Call
AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our third-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time.
Non-GAAP Financial Results
Financial results for 2023 and 2022 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
AbbVie Inc. Key Product Revenues Quarter Ended September 30, 2023 (Unaudited) | |||||||||||||||
% Change vs. 3Q22 | |||||||||||||||
Net Revenues (in millions) | Reported | Operationala | |||||||||||||
U.S. | Int'l. | Total | U.S. | Int'l. | Total | Int'l. | Total | ||||||||
NET REVENUES | $10,852 | $3,075 | $13,927 | (7.7) % | 0.8 % | (6.0) % | 1.4 % | (5.8) % | |||||||
Immunology | 5,696 | 1,087 | 6,783 | (14.7) | 12.1 | (11.3) | 11.9 | (11.3) | |||||||
Humira | 3,020 | 527 | 3,547 | (39.1) | (12.6) | (36.2) | (12.2) | (36.2) | |||||||
Skyrizi | 1,875 | 251 | 2,126 | 53.5 | 42.5 | 52.1 | 40.7 | 51.9 | |||||||
Rinvoq | 801 | 309 | 1,110 | 59.0 | 61.8 | 59.8 | 61.2 | 59.6 | |||||||
Oncology | 973 | 539 | 1,512 | (12.3) | (0.4) | (8.4) | (1.0) | (8.6) | |||||||
Imbruvicab | 678 | 230 | 908 | (20.2) | (19.6) | (20.0) | (19.6) | (20.0) | |||||||
Venclexta | 281 | 309 | 590 | 8.1 | 21.1 | 14.6 | 19.9 | 14.0 | |||||||
Epkinlyc | 14 | — | 14 | n/m | n/m | n/m | n/m | n/m | |||||||
Aesthetics | 759 | 480 | 1,239 | — | (11.4) | (4.7) | (9.7) | (4.0) | |||||||
Botox Cosmetic | 388 | 232 | 620 | 5.0 | (13.3) | (2.7) | (10.9) | (1.7) | |||||||
Juvederm Collection | 116 | 205 | 321 | (6.4) | (9.8) | (8.6) | (8.7) | (7.9) | |||||||
Other Aesthetics | 255 | 43 | 298 | (4.0) | (8.1) | (4.6) | (7.0) | (4.4) | |||||||
Neuroscience | 1,817 | 226 | 2,043 | 24.0 | 8.9 | 22.1 | 8.4 | 22.0 | |||||||
Botox Therapeutic | 626 | 122 | 748 | 7.2 | 6.5 | 7.1 | 8.6 | 7.4 | |||||||
Vraylar | 750 | 1 | 751 | 35.2 | >100.0 | 35.4 | >100.0 | 35.4 | |||||||
Duodopa | 25 | 93 | 118 | 10.6 | 6.6 | 7.4 | 2.3 | 4.0 | |||||||
Ubrelvy | 230 | 3 | 233 | 43.7 | >100.0 | 45.6 | >100.0 | 45.6 | |||||||
Qulipta | 131 | 1 | 132 | >100.0 | n/m | >100.0 | n/m | >100.0 | |||||||
Other Neuroscience | 55 | 6 | 61 | (31.9) | 6.2 | (29.9) | 9.6 | (29.7) | |||||||
Eye Care | 310 | 295 | 605 | (14.0) | 13.1 | (2.7) | 13.9 | (2.4) | |||||||
Ozurdex | 34 | 86 | 120 | (4.5) | 22.3 | 13.2 | 21.7 | 12.8 | |||||||
Lumigan/Ganfort | 28 | 63 | 91 | (53.0) | 2.7 | (24.8) | 1.4 | (25.5) | |||||||
Alphagan/Combigan | 30 | 40 | 70 | (16.0) | 10.1 | (3.1) | 17.3 | 0.4 | |||||||
Restasis | 104 | 13 | 117 | (20.7) | 35.0 | (17.0) | 42.1 | (16.5) | |||||||
Other Eye Care | 114 | 93 | 207 | 16.3 | 11.9 | 14.2 | 12.0 | 14.2 | |||||||
Other Key Products | 751 | 212 | 963 | (4.6) | 4.4 | (2.8) | 4.9 | (2.7) | |||||||
Mavyret | 167 | 203 | 370 | (12.3) | 5.2 | (3.5) | 5.8 | (3.2) | |||||||
Creon | 305 | — | 305 | (9.1) | n/m | (9.1) | n/m | (9.1) | |||||||
Linzess/Constella | 279 | 9 | 288 | 6.8 | (11.1) | 6.2 | (13.0) | 6.1 |
a | "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. |
b | Reflects profit sharing for Imbruvica international revenues. |
c | Reflects profit sharing for Epkinly U.S. revenues. |
n/m = not meaningful |
AbbVie Inc. Key Product Revenues Nine Months Ended September 30, 2023 (Unaudited) | |||||||||||||||
% Change vs. 9M22 | |||||||||||||||
Net Revenues (in millions) | Reported | Operationala | |||||||||||||
U.S. | Int'l. | Total | U.S. | Int'l. | Total | Int'l. | Total | ||||||||
NET REVENUES | $30,773 | $9,244 | $40,017 | (8.2) % | (1.8) % | (6.8) % | 1.6 % | (6.0) % | |||||||
Immunology | 15,963 | 3,220 | 19,183 | (10.9) | 4.6 | (8.6) | 8.1 | (8.1) | |||||||
Humira | 9,420 | 1,680 | 11,100 | (30.8) | (17.9) | (29.1) | (14.8) | (28.7) | |||||||
Skyrizi | 4,648 | 721 | 5,369 | 50.9 | 41.8 | 49.6 | 45.5 | 50.1 | |||||||
Rinvoq | 1,895 | 819 | 2,714 | 54.4 | 56.1 | 54.9 | 61.0 | 56.4 | |||||||
Oncology | 2,807 | 1,599 | 4,406 | (15.6) | (1.3) | (10.9) | 0.2 | (10.4) | |||||||
Imbruvicab | 1,982 | 711 | 2,693 | (23.4) | (18.0) | (22.0) | (18.0) | (22.0) | |||||||
Venclexta | 811 | 888 | 1,699 | 9.4 | 18.1 | 13.8 | 21.4 | 15.5 | |||||||
Epkinlyc | 14 | — | 14 | n/m | n/m | n/m | n/m | n/m | |||||||
Aesthetics | 2,365 | 1,558 | 3,923 | (4.9) | — | (3.0) | 5.3 | (1.0) | |||||||
Botox Cosmetic | 1,217 | 747 | 1,964 | (1.1) | 0.7 | (0.4) | 6.0 | 1.6 | |||||||
Juvederm Collection | 363 | 681 | 1,044 | (13.3) | (0.8) | (5.6) | 4.5 | (2.3) | |||||||
Other Aesthetics | 785 | 130 | 915 | (6.3) | 0.5 | (5.4) | 5.4 | (4.7) | |||||||
Neuroscience | 4,929 | 694 | 5,623 | 18.0 | 7.9 | 16.7 | 11.7 | 17.2 | |||||||
Botox Therapeutic | 1,827 | 388 | 2,215 | 11.3 | 10.9 | 11.3 | 16.6 | 12.3 | |||||||
Vraylar | 1,967 | 3 | 1,970 | 33.6 | >100.0 | 33.7 | >100.0 | 33.7 | |||||||
Duodopa | 74 | 279 | 353 | 2.8 | — | 0.6 | 1.1 | 1.5 | |||||||
Ubrelvy | 574 | 7 | 581 | 18.8 | >100.0 | 20.3 | >100.0 | 20.3 | |||||||
Qulipta | 292 | 2 | 294 | >100.0 | n/m | >100.0 | n/m | >100.0 | |||||||
Other Neuroscience | 195 | 15 | 210 | (51.3) | 6.4 | (49.3) | 11.8 | (49.1) | |||||||
Eye Care | 938 | 892 | 1,830 | (25.8) | 5.5 | (13.3) | 9.0 | (11.9) | |||||||
Ozurdex | 107 | 247 | 354 | 2.6 | 13.1 | 9.7 | 16.1 | 11.7 | |||||||
Lumigan/Ganfort | 142 | 198 | 340 | (23.6) | (3.1) | (12.9) | (0.9) | (11.8) | |||||||
Alphagan/Combigan | 90 | 116 | 206 | (43.5) | 4.2 | (24.0) | 10.6 | (21.4) | |||||||
Restasis | 265 | 43 | 308 | (48.8) | 14.2 | (44.5) | 20.1 | (44.1) | |||||||
Other Eye Care | 334 | 288 | 622 | 13.0 | 5.1 | 9.2 | 8.6 | 10.9 | |||||||
Other Key Products | 2,222 | 616 | 2,838 | (1.0) | (1.2) | (1.1) | 2.1 | (0.4) | |||||||
Mavyret | 531 | 590 | 1,121 | (5.6) | (1.5) | (3.5) | 1.8 | (1.8) | |||||||
Creon | 892 | — | 892 | (5.2) | n/m | (5.2) | n/m | (5.2) | |||||||
Linzess/Constella | 799 | 26 | 825 | 7.7 | 7.0 | 7.7 | 9.3 | 7.8 |
a | "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. |
b | Reflects profit sharing for Imbruvica international revenues. |
c | Reflects profit sharing for Epkinly U.S. revenues. |
n/m = not meaningful |
AbbVie Inc. Consolidated Statements of Earnings (Unaudited) | |||||||
(in millions, except per share data) | Third Quarter Ended September 30 | Nine Months Ended September 30 | |||||
2023 | 2022 | 2023 | 2022 | ||||
Net revenues | $ 13,927 | $ 14,812 | $ 40,017 | $ 42,933 | |||
Cost of products sold | 6,485 | 5,022 | 14,711 | 13,244 | |||
Selling, general and administrative | 3,372 | 3,304 | 9,679 | 11,843 | |||
Research and development | 1,723 | 1,614 | 5,748 | 4,720 | |||
Acquired IPR&D and milestones | 66 | 40 | 496 | 454 | |||
Other operating expense (income), net | — | 229 | (179) | 57 | |||
Total operating costs and expenses | 11,646 | 10,209 | 30,455 | 30,318 | |||
Operating earnings | 2,281 | 4,603 | 9,562 | 12,615 | |||
Interest expense, net | 398 | 497 | 1,306 | 1,568 | |||
Net foreign exchange loss | 25 | 36 | 97 | 108 | |||
Other expense (income), net | (95) | (330) | 3,121 | 427 | |||
Earnings before income tax expense | 1,953 | 4,400 | 5,038 | 10,512 | |||
Income tax expense | 172 | 448 | 989 | 1,139 | |||
Net earnings | 1,781 | 3,952 | 4,049 | 9,373 | |||
Net earnings attributable to noncontrolling interest | 3 | 3 | 8 | 10 | |||
Net earnings attributable to AbbVie Inc. | $ 1,778 | $ 3,949 | $ 4,041 | $ 9,363 | |||
Diluted earnings per share attributable to AbbVie Inc. | $ 1.00 | $ 2.21 | $ 2.26 | $ 5.24 | |||
Adjusted diluted earnings per sharea | $ 2.95 | $ 3.66 | $ 8.32 | $ 10.18 | |||
Weighted-average diluted shares outstanding | 1,771 | 1,776 | 1,772 | 1,777 |
a Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Quarter Ended September 30, 2023 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 1,953 | $ 1,778 | $ 1.00 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 2,039 | 1,728 | 0.98 | ||
Intangible asset impairment | 2,114 | 1,660 | 0.93 | ||
Acquisition and integration costs | 60 | 54 | 0.03 | ||
Change in fair value of contingent consideration | 8 | 8 | — | ||
Other | 59 | 22 | 0.01 | ||
As adjusted (non-GAAP) | $ 6,233 | $ 5,250 | $ 2.95 |
a Represents net earnings attributable to AbbVie Inc. | |||||||
Intangible asset impairment reflects a partial impairment charge related to the U.S. Imbruvica intangible asset acquired as part | |||||||
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2023 included acquired | |||||||
2. The impact of the specified items by line item was as follows: | |||||||
Quarter Ended September 30, 2023 | |||||||
(in millions) | Cost of | SG&A | R&D | Other | |||
As reported (GAAP) | $ 6,485 | $ 3,372 | $ 1,723 | $ (95) | |||
Adjusted for specified items: | |||||||
Intangible asset amortization | (2,039) | — | — | — | |||
Intangible asset impairment | (2,114) | — | — | — | |||
Acquisition and integration costs | (18) | (40) | (2) | — | |||
Change in fair value of contingent consideration | — | — | — | (8) | |||
Other | (13) | (2) | (1) | (43) | |||
As adjusted (non-GAAP) | $ 2,301 | $ 3,330 | $ 1,720 | $ (146) |
3. The adjusted tax rate for the third quarter of 2023 was 15.7 percent, as detailed below: | |||||
Quarter Ended September 30, 2023 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 1,953 | $ 172 | 8.8 % | ||
Specified items | 4,280 | 808 | 18.9 % | ||
As adjusted (non-GAAP) | $ 6,233 | $ 980 | 15.7 % |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Quarter Ended September 30, 2022 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 4,400 | $ 3,949 | $ 2.21 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 2,024 | 1,673 | 0.94 | ||
Intangible asset impairment | 770 | 604 | 0.34 | ||
Acquisition and integration costs | 348 | 348 | 0.20 | ||
Change in fair value of contingent consideration | (214) | (218) | (0.12) | ||
Litigation matters | 110 | 94 | 0.05 | ||
Other | 58 | 78 | 0.04 | ||
As adjusted (non-GAAP) | $ 7,496 | $ 6,528 | $ 3.66 |
a Represents net earnings attributable to AbbVie Inc. | ||||||||||
Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition. Other primarily | ||||||||||
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2022 included acquired | ||||||||||
2. The impact of the specified items by line item was as follows: | ||||||||||
Quarter Ended September 30, 2022 | ||||||||||
(in millions) | Cost of | SG&A | R&D | Other | Other | |||||
As reported (GAAP) | $ 5,022 | $ 3,304 | $ 1,614 | $ 229 | $ (330) | |||||
Adjusted for specified items: | ||||||||||
Intangible asset amortization | (2,024) | — | — | — | — | |||||
Intangible asset impairment | (770) | — | — | — | — | |||||
Acquisition and integration costs | (22) | (91) | (6) | (229) | — | |||||
Change in fair value of contingent consideration | — | — | — | — | 214 | |||||
Litigation matters | — | (110) | — | — | — | |||||
Other | (39) | (14) | (1) | — | (4) | |||||
As adjusted (non-GAAP) | $ 2,167 | $ 3,089 | $ 1,607 | $ — | $ (120) |
3. The adjusted tax rate for the third quarter of 2022 was 12.9 percent, as detailed below: | |||||
Quarter Ended September 30, 2022 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 4,400 | $ 448 | 10.2 % | ||
Specified items | 3,096 | 517 | 16.7 % | ||
As adjusted (non-GAAP) | $ 7,496 | $ 965 | 12.9 % |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Nine Months Ended September 30, 2023 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 5,038 | $ 4,041 | $ 2.26 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 6,057 | 5,101 | 2.87 | ||
Intangible asset impairment | 2,824 | 2,289 | 1.29 | ||
Acquisition and integration costs | 38 | 15 | 0.01 | ||
Change in fair value of contingent consideration | 3,432 | 3,348 | 1.88 | ||
Other | 75 | 16 | 0.01 | ||
As adjusted (non-GAAP) | $ 17,464 | $ 14,810 | $ 8.32 |
a Represents net earnings attributable to AbbVie Inc. | |||||||||
Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time | |||||||||
Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2023 included acquired | |||||||||
2. The impact of the specified items by line item was as follows: | |||||||||
Nine Months Ended September 30, 2023 | |||||||||
(in millions) | Cost of | SG&A | R&D | Other | Other | ||||
As reported (GAAP) | $ 14,711 | $ 9,679 | $ 5,748 | $ (179) | $ 3,121 | ||||
Adjusted for specified items: | |||||||||
Intangible asset amortization | (6,057) | — | — | — | — | ||||
Intangible asset impairment | (2,194) | — | (630) | — | — | ||||
Acquisition and integration costs | (66) | (134) | (7) | 169 | — | ||||
Change in fair value of contingent consideration | — | — | — | — | (3,432) | ||||
Other | (45) | (13) | (4) | 10 | (23) | ||||
As adjusted (non-GAAP) | $ 6,349 | $ 9,532 | $ 5,107 | $ — | $ (334) |
3. The adjusted tax rate for the first nine months of 2023 was 15.2 percent, as detailed below: | |||||
Nine Months Ended September 30, 2023 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 5,038 | $ 989 | 19.6 % | ||
Specified items | 12,426 | 1,657 | 13.3 % | ||
As adjusted (non-GAAP) | $ 17,464 | $ 2,646 | 15.2 % |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) | |||||
1. Specified items impacted results as follows: | |||||
Nine Months Ended September 30, 2022 | |||||
(in millions, except per share data) | Earnings | Diluted | |||
Pre-tax | After-taxa | EPS | |||
As reported (GAAP) | $ 10,512 | $ 9,363 | $ 5.24 | ||
Adjusted for specified items: | |||||
Intangible asset amortization | 5,728 | 4,794 | 2.69 | ||
Intangible asset impairment | 770 | 604 | 0.34 | ||
Acquisition and integration costs | 595 | 567 | 0.32 | ||
Change in fair value of contingent consideration | 647 | 657 | 0.37 | ||
Pylera divestiture | (172) | (126) | (0.07) | ||
Litigation matters | 2,497 | 2,021 | 1.13 | ||
Other | 281 | 295 | 0.16 | ||
As adjusted (non-GAAP) | $ 20,858 | $ 18,175 | $ 10.18 |
a Represents net earnings attributable to AbbVie Inc. | |||||||||
Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition. Litigation matters | |||||||||
Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2022 included acquired | |||||||||
2. The impact of the specified items by line item was as follows: | |||||||||
Nine Months Ended September 30, 2022 | |||||||||
(in millions) | Cost of | SG&A | R&D | Other | Other | ||||
As reported (GAAP) | $ 13,244 | $ 11,843 | $ 4,720 | $ 57 | $ 427 | ||||
Adjusted for specified items: | |||||||||
Intangible asset amortization | (5,728) | — | — | — | — | ||||
Intangible asset impairment | (770) | — | — | — | — | ||||
Acquisition and integration costs | (84) | (263) | (19) | (229) | — | ||||
Change in fair value of contingent consideration | — | — | — | — | (647) | ||||
Pylera divestiture | — | — | — | 172 | — | ||||
Litigation matters | — | (2,497) | — | — | — | ||||
Other | (160) | (107) | (7) | — | (7) | ||||
As adjusted (non-GAAP) | $ 6,502 | $ 8,976 | $ 4,694 | $ — | $ (227) |
3. The adjusted tax rate for the first nine months of 2022 was 12.8 percent, as detailed below: | |||||
Nine Months Ended September 30, 2022 | |||||
(dollars in millions) | Pre-tax | Income taxes | Tax rate | ||
As reported (GAAP) | $ 10,512 | $ 1,139 | 10.8 % | ||
Specified items | 10,346 | 1,534 | 14.8 % | ||
As adjusted (non-GAAP) | $ 20,858 | $ 2,673 | 12.8 % |
SOURCE AbbVie
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?